Xinias Ioannis, Mavroudi Antigoni, Vrani Olga, Imvrios Georgios, Takoudas Dimitrios, Spiroglou Kleomenis
3 Department of Pediatrics, Aristotle University, Hippokration General Hospital, Thessaloniki, Greece;
Pediatr Rep. 2010 Sep 6;2(2):e14. doi: 10.4081/pr.2010.e14.
Liver transplantation (LT) is the only available live-saving procedure for children with irreversible liver failure. This paper reports our experience from the follow-up of 16 Greek children with end-stage liver failure who underwent a LT. Over a period of 15 years, 16 pediatric liver recipients received follow up after being subjected to OLT (orthotopic liver transplantation) due to end-stage liver failure. Nine children initially presented with extrahepatic biliary atresia, 2 with acute liver failure after toxic mushroom ingestion, 2 with intrahepatic cholestasis, 2 with metabolic diseases and one with hepatoblastoma. Ten children received a liver transplant in the Organ Transplantation Unit of Aristotle University of Thessaloniki and the rest in other transplant centers. Three transplants came from a living-related donor and 13 from a deceased donor. Six children underwent immunosuppressive treatment with cyclosporine, mycophenolate mofetil and corticosteroids, and 7 with tacrolimus, mycophenolate mofetil and corticosteroids. Three out of 16 children died within the first month after the transplantation due to post-transplant complications. Three children presented with acute rejection and one with chronic organ rejection which was successfully managed. Five children presented with cytomegalovirus infection, 5 with Epstein-Barr virus, 2 with HSV(1,2), 2 with ParvoB19 virus, 2 with varicella-zoster virus and one with C. Albicans infection. One child presented with upper gastrointestinal hemorrhage and one with small biliary paucity. A satisfying outcome was achieved in most cases, with good graft function, except for the patient with small biliary paucity who required re-transplantation.The long-term clinical course of liver transplanted children is good under the condition that they are attended in specialized centers.
肝移植(LT)是患有不可逆肝衰竭儿童唯一可行的挽救生命的手术。本文报告了我们对16例接受肝移植的希腊终末期肝衰竭儿童的随访经验。在15年的时间里,16名儿童肝移植受者因终末期肝衰竭接受原位肝移植(OLT)后接受了随访。9名儿童最初表现为肝外胆道闭锁,2名因食用有毒蘑菇后出现急性肝衰竭,2名患有肝内胆汁淤积,2名患有代谢性疾病,1名患有肝母细胞瘤。10名儿童在塞萨洛尼基亚里士多德大学器官移植科接受了肝移植,其余在其他移植中心。3例移植来自活体亲属供体,13例来自尸体供体。6名儿童接受了环孢素、霉酚酸酯和皮质类固醇的免疫抑制治疗,7名接受了他克莫司、霉酚酸酯和皮质类固醇的治疗。16名儿童中有3名在移植后第一个月内由于移植后并发症死亡。3名儿童出现急性排斥反应,1名出现慢性器官排斥反应,但成功得到处理。5名儿童出现巨细胞病毒感染,5名出现EB病毒感染,2名出现单纯疱疹病毒(1,2型)感染,2名出现细小病毒B19感染,2名出现水痘带状疱疹病毒感染,1名出现白色念珠菌感染。1名儿童出现上消化道出血,1名出现小胆管稀少。除了需要再次移植的小胆管稀少患者外,大多数病例都取得了令人满意的结果,移植肝功能良好。在专科中心的照料下,肝移植儿童的长期临床病程良好。